New: Introducing the Finviz Crypto Map

Learn More

Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation

By Maham Fatima | July 31, 2025, 11:40 PM

Alector Inc. (NASDAQ:ALEC) is one of the stocks under $10 to buy now. On July 28, Mizuho upgraded Alector from Neutral to Outperform, while raising the price target from $2.50 to $3.50. The decision reflected Mizuho’s belief that the pessimism surrounding Alector’s shares is excessive, especially considering the company’s cash position of ~$350 million, which is roughly double its current valuation.

Mizuho’s confidence is also driven by feedback from key opinion leaders regarding latozinemab, which is Alector’s lead asset for frontotemporal dementia/FTD, raising its probability of success from 50% to 60%. The firm favors the stock in anticipation of the Phase 3 data for latozinemab, expected in Q4 2025. The company is advancing its clinical pipeline, with the INFRONT-3 Phase 3 trial for latozinemab on schedule for topline data release in Q4 2025.

Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation
A biotechnologist in a white lab coat manipulating genes in a laboratory.

In Q1 2025, Alector reported revenue of $3.7 million, which fell short of the estimated $4.38 million. The revenue decline from $15.9 million in Q1 2024 was due to the completion of performance obligations related to the AL002 program and the latozinemab FTD-C9orf72 Phase 2 trial in late 2024. However, the net loss per share of $0.41 was better than the estimated loss of $0.48 per share.

Alector Inc. (NASDAQ:ALEC) is a late-stage clinical biotechnology company that develops therapies that are focused on counteracting the devastating progression of neurodegenerative diseases.

While we acknowledge the potential of ALEC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

Mentioned In This Article

Latest News